Publications by authors named "Corina Becker"

Claim this Profile
C
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
Achim Fritsch, Michaela Meyer, Robert O Blaustein, Maria E Trujillo, Eunkyung Kauh, Corina Becker

Clin Pharmacokinet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
Sebastian Frechen, Ibrahim Ince, André Dallmann, Michael Gerisch, Natalia A Jungmann, Corina Becker

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches.
Hauke Ruehs, Alexander Solms, Matthias Frei, Corina Becker, Maria E Trujillo

Clin Pharmacokinet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults".
Michael Boettcher, Corina Becker

Clin Pharmacokinet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Corina Becker

Am J Cardiovasc Drugs· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.
Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker

Clin Pharmacokinet· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
Maria E Trujillo, Leticia Arrington, Yogesh Patel, Julie Passarell, Larissa Wenning, Corina Becker

Clin Pharmacol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vericiguat in Combination with Short-Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study.
Michael Boettcher, Hans-Dirk Düngen, Frank Donath, Gerd Mikus, Nikos Werner, Corina Becker

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.
Michael Boettcher, Gerd Mikus, Dietmar Trenk, Hans-Dirk Düngen, Frank Donath, Corina Becker

Clin Transl Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Hauke Ruehs, Dagmar Klein, Matthias Frei, Joachim Grevel, Rupert Austin, Corina Becker

Clin Pharmacokinet· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
Michael Boettcher, Dirk Thomas, Wolfgang Mueck, Stephanie Loewen, Erich Arens, Corina Becker

Eur J Clin Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
Michael Boettcher, Stephanie Loewen, Mireille Gerrits, Corina Becker

Clin Pharmacokinet· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
Michael Boettcher, Michael Gerisch, Maximilian Lobmeyer, Nina Besche, Dirk Thomas, Corina Becker

Clin Pharmacokinet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker

Pulm Circ· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
Reiner Frey, Corina Becker, Soundos Saleh, Sigrun Unger, Dorina van der Mey

Clin Pharmacokinet· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.
Corina Becker, Reiner Frey, Christiane Hesse, Sigrun Unger, Michael Reber

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Corina Becker, Sigrun Unger, Anja Schmidt, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
Corina Becker, Reiner Frey, Sigrun Unger, Ulrike Artmeier-Brandt, Gerrit Weimann

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
Corina Becker, Reiner Frey, Sigrun Unger, Dirk Thomas, Michael Reber

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Corina Becker, Sigrun Unger, Anja Schmidt, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Soundos Saleh, Corina Becker, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
Soundos Saleh, Reiner Frey, Corina Becker, Sigrun Unger, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.
Soundos Saleh, Corina Becker, Reiner Frey, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
Soundos Saleh, Corina Becker, Reiner Frey, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
Reiner Frey, Sigrun Unger, Dorina van der Mey, Corina Becker, Soundos Saleh

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis